News2020-07-17T11:41:26-04:00
Jun 212022

Halberd Creates Subsidiary to Apply Its Patented Technology to Treat Cancer

June 21st, 2022|Categories: Featured, Investor News, News|Tags: , , , , , , , , |

Recognizing the breadth of application of its patented extracorporeal treatment approach, Halberd Corporation (OTC-PINK: "HALB”) announced the creation of a subgroup of researchers to focus on cancer treatment.  Halberd’s technology is capable of being applied to many diseases, and management decided to not delay the development of potential cancer treatments. The subgroup will be guided by Halberd’s existing technical team members, but will add the necessary expertise to carry the program forward without diluting its ...

Jun 82022

Halberd Corp. & Mississippi State University Discuss Animal Testing as Prelude to FDA Certification

June 8th, 2022|Categories: Featured, Investor News, News, Press Releases|Tags: , , , , , |

Jackson Center, PA, June 8, 2022 – Halberd Corporation (OTC-PINK: "HALB”) and Mississippi State University (MSU) executed a non-disclosure agreement (NDA) to explore animal testing as the next step in obtaining FDA certification for Halberd’s patented extracorporeal disease eradication processes.  Consistent with its press release of May 18, 2022, Halberd commenced its pursuits with mdi Consultants, Inc, an FDA application consulting firm, and the FDA to determine specific animal testing requirements.  Animal testing will be ...

May 242022

Halberd Successfully Eliminates Excess Levels of Inflammatory Cytokines

May 24th, 2022|Categories: Featured, Investor News, News|Tags: , , , , , , , |

Jackson Center, PA, May 24, 2022 – Halberd Corporation (OTC-PINK: "HALB”) researchers have demonstrated a protocol which allows for the precise level of elimination of a specific targeted cytokine from a homogeneous mixture of two different cytokines in a fluid.  Several adverse health conditions are caused by excess quantities of particular components in blood or cerebral spinal fluid (CSF), such as proteins, cytokines, amino acids, etc.  Elimination of excessive quantities of these elements is key ...

May 182022

Halberd Engages Professional Firm to Proceed with FDA Filings

May 18th, 2022|Categories: Investor News, News, Press Releases|Tags: , |

Jackson Center, PA, May 18, 2022 – Halberd Corporation (OTC-PINK: "HALB”) has engaged the services of mdi Consultants, Inc. (mdi) to assist Halberd in navigating the U.S. Food and Drug Administration’s (FDA) complex application and certification processes.  mdi will guide Halberd on the FDA application and testing protocol and assist in filing the appropriate documents and disclosures with the FDA in each stage of the process.  After numerous discussions, Halberd is confident that mdi is ...

May 122022

Halberd Submits Audited Financials; Files Form-10 as First Step to Up-list to OTCQB

May 12th, 2022|Categories: Investor News, News, Press Releases|Tags: , , , , , |

Jackson Center, PA, May 12, 2022 – Halberd Corporation (OTC-PINK: "HALB”) submitted its fully audited financials through its fiscal second quarter and Form-10 to the SEC as its initial step to up-list from OTC-PINK to OTCQB on the OTC Markets exchange.  Once Halberd’s shares are qualified under the Securities Exchange Act of 1934 (the “34 Act”), Halberd will become a fully reporting issuer pursuant to Section 12(g) of the ’34 Act.   The OTCQB index is ...

Apr 272022

Dr. Gregg Sturrus’ TEDx Talk Features Halberd’s Extracorporeal Treatment of Neurodegenerative Diseases

April 27th, 2022|Categories: Medical, News, Videos|

Jackson Center, PA, April 27, 2022 – A key member of Halberd Corporation’s (OTC PINK:HALB) Research Team, Dr. W. Gregg Sturrus, recently gave a TEDx Talk® on Halberd’s patented and patent-pending extracorporeal elimination of neurodegenerative disease proteins and cytokines using lasers and metallic nanoparticles. Dr. Sturrus, in his talk, provided a brief history of the evolution of the technology and outlines the innovative Halberd approach to potentially treating neurodegenerative diseases, as well ...

Go to Top